Overview on visceral manifestations of mitochondrial disorders

J. Finsterer
Neurological Department, Krankenanstalt Rudolfstiftung, Vienna, Austria, tel.: +43 (0)1-71165-92085, fax: +43 (0)1-478 17 11, e-mail: duarte@aonmail.at

ABSTRACT

Mitochondriopathies (MCPs) that reach adult age not only manifest in the central and peripheral nervous systems, eyes, ears, and dermis, but also in visceral organs, such as endocrine organs, heart, liver, guts, kidneys and blood. Visceral manifestations occur as part of a multisystem involvement or rarely as single organ affection. Endocrinological abnormalities are found in the MELAS, MERRF, KSS, MIDD and DIDMOAD syndromes. Cardiac involvement occurs in the MELAS, MERRF, KSS, CPEO, LHON, NARP, and Leigh syndromes. Gastrointestinal manifestations are common in the MERRF, MNGIE, DIDMOAD, and Leigh syndromes. Mitochondrial syndromes with renal manifestations are the KSS, Pearson, DIDMOAD, and Leigh syndromes. The haematopoetic system is affected in the KSS, MERRF, and Leigh syndromes. In addition, visceral manifestations are found in many nonsyndromic MCPs. Although there is no causal therapy for MCPs, adequate symptomatic therapy, particularly of visceral manifestations, markedly improves quality of life and prognosis of these still often neglected or overlooked disorders.

KEYWORDS

Internal medicine, mitochondrial, neuromuscular, respiratory chain, visceral organs

INTRODUCTION

Mitochondriopathies (MCPs) were long regarded as disorders affecting almost exclusively the peripheral or central nervous system (encephalomyopathies). However, it turned out that MCPs are multisystem disorders in the majority of cases, also affecting eyes, ears, endocrine organs, heart, guts, liver, kidneys, blood, and dermis. Since MCPs may cause any symptom, in any organ, at any age, the clinical presentation is quite heterogeneous. In rare cases only a single organ is affected, but multisystem involvement may develop with progression of the disease. Possible manifestations of visceral organs are summarised in table 1. Various combinations of organ involvement led to the definition of mitochondrial syndromes, of which some are well known for their acronyms. The majority of MCPs, however, do not fit into one of these disease categories. Mitochondrial syndromes with visceral manifestations are listed in tables 2 and 3.

AETIOLOGY

MCPs are either due to genetic causes (primary MCPs) or to nongenetic endogenous or exogenous disturbances of mitochondrial functions (secondary MCPs). Genetic

Table 1. Visceral manifestations of mitochondriopathies

<table>
<thead>
<tr>
<th>System</th>
<th>Conditions/Manifestations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Endocrinological system</td>
<td>Hypopituitarism, short stature, diabetes insipidus, hypothyroidism, hyperparathyroidism, hyperthyroidism, polyphagia, polydypsia, hyperhidrosis, insufficiency of the suprarenal gland, hyponatremia, hypokalaemia, hyperlipidaemia, amenorrhoea, hypogonadism, gynaecomastia, sicca syndrome, osteoporosis</td>
</tr>
<tr>
<td>Heart</td>
<td>Cardiomyopathy, rhythm abnormalities, left ventricular hypertrabeculation, Takotsubo phenomenon</td>
</tr>
<tr>
<td>Gastrointestinal</td>
<td>Parasodiostis, dysphagia, gastrointestinal dysmotility, pseudo-obstruction, recurrent vomiting, hepatopathy, recurrent pancreatitis, exocrine pancreas insufficiency, villous atrophy, malabsorption, diarrhoea, weight loss, anorexia</td>
</tr>
<tr>
<td>Kidneys</td>
<td>Renal cysts, tubulopathy, focal-segmental glomerulosclerosis, Toni-Debre-Fanconi syndrome</td>
</tr>
<tr>
<td>Blood</td>
<td>Anaemia, leucopenia, thrombocytopenia, eosinophilia</td>
</tr>
</tbody>
</table>
### Table 2. Syndromic mitochondrial mitochondrialopathies with visceral manifestations

<table>
<thead>
<tr>
<th>Acronym</th>
<th>Translation</th>
<th>Endocrine organs</th>
<th>Heart</th>
<th>Guts</th>
<th>Kidney</th>
<th>Blood</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPEO</td>
<td>Chronic progressive external ophthalmoplegia</td>
<td>N</td>
<td>Rhythm abnormalities</td>
<td>Hepatopathy</td>
<td>Toni-Debre-Fancon syndrome</td>
<td>Anaemia</td>
</tr>
<tr>
<td>KSS</td>
<td>Kearns-Sayre syndrome</td>
<td>Short stature, diabetes,</td>
<td>Rhythm abnormalities, Dysphagia</td>
<td>N</td>
<td>N</td>
<td>N</td>
</tr>
<tr>
<td>MELAS</td>
<td>Mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes</td>
<td>Dilative cardiomyopathy,</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>Megaloblastic</td>
</tr>
<tr>
<td>MERRF</td>
<td>Myoclonic epilepsy and ragged red fibres</td>
<td>N</td>
<td>Cardiomyopathy, LVHT</td>
<td>N</td>
<td>N</td>
<td>Pancytopenia</td>
</tr>
<tr>
<td>MIDD</td>
<td>Maternally inherited diabetes and deafness</td>
<td>Diabetes</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
</tr>
<tr>
<td>LHON</td>
<td>Leber's hereditary optic neuropathy</td>
<td>N</td>
<td>Rhythm abnormalities, LVHT</td>
<td>N</td>
<td>N</td>
<td>N</td>
</tr>
<tr>
<td>NARP</td>
<td>Neurogenic muscle weakness, ataxia, retinitis pigmentosa</td>
<td>N</td>
<td>Cardiomyopathy, LVHT</td>
<td>N</td>
<td>N</td>
<td>N</td>
</tr>
<tr>
<td>MILS</td>
<td>Maternally inherited Leigh's syndrome</td>
<td>Lactacidosis</td>
<td>Hypotonia</td>
<td>N</td>
<td>N</td>
<td>N</td>
</tr>
</tbody>
</table>

LVHT = left ventricular hypertrabeculation; N = no manifestation.

### Table 3. Syndromic and nonsyndromic nuclear mitochondrialopathies with visceral manifestations

<table>
<thead>
<tr>
<th>Syndrome</th>
<th>Mutated respiratory chain complexes</th>
<th>Mutated gene(s)</th>
<th>Inner organ manifestation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leigh's syndrome</td>
<td>NDUF5a, NDUF5b, NDUF5c, NDUF5d, NDUF5e, SDHA, CoQ10</td>
<td></td>
<td>Hypotonia, vomiting, cardiomyopathy</td>
</tr>
<tr>
<td>Cardioencephalomyopathy syndrome</td>
<td>NDUF5a</td>
<td>SDHB</td>
<td>Cardiomyopathy</td>
</tr>
<tr>
<td>NN</td>
<td>SDHC, SDHD</td>
<td></td>
<td>Hereditary paraganglioma</td>
</tr>
<tr>
<td>Mutated assembly factors</td>
<td>SURF1, LRPRRC</td>
<td></td>
<td>Hypotonia, vomiting, hypertrophic cardiomyopathy</td>
</tr>
<tr>
<td>NN</td>
<td>SCO1</td>
<td></td>
<td>Ketaocidotic coma, hepatopathy</td>
</tr>
<tr>
<td>NN</td>
<td>SCO2</td>
<td></td>
<td>Cardiomyopathy</td>
</tr>
<tr>
<td>NN</td>
<td>COX10</td>
<td></td>
<td>Tubulopathy</td>
</tr>
<tr>
<td>NN</td>
<td>COX15</td>
<td></td>
<td>Hypertrophic cardiomyopathy</td>
</tr>
<tr>
<td>NN</td>
<td>BCSD1</td>
<td></td>
<td>Neonatal proximal tubulopathy, hepatopathy</td>
</tr>
<tr>
<td>Mutated proteins responsible for mtDNA stability (depletion and multiple deletions of mtDNA)</td>
<td>MNGIE, DGUK, DIDMOAD</td>
<td></td>
<td>Osteoporosis, malabsorption, gastroparesis, pseudo-obstruction, gastrointestinal dysmotility, Hepatopathy, Diabetes mellitus, diabetes insipidus, optic atrophy, deafness, dysmotility, hypopituitarism, hypogonadism</td>
</tr>
<tr>
<td>NN</td>
<td>WFS1, WFS2</td>
<td></td>
<td>Barths syndrome: Cardiomyopathy, LVHT, neutropenia, short stature, lactacoidic aciduria</td>
</tr>
<tr>
<td>Mutated factors involved in the biogenesis of mitochondria</td>
<td>ABC7</td>
<td></td>
<td>Friedreich's ataxia: Hypertrrophic cardiomyopathy</td>
</tr>
<tr>
<td>NN</td>
<td>TAZ</td>
<td></td>
<td>Mohr-Tranejaerg syndrome: Deafness, dystonia, cortical blindness, cataract, spasticity, dysphagia</td>
</tr>
<tr>
<td>Ataxia/sideroblastic anaemia syndrome</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Barth's syndrome</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Friedreich's ataxia</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mohr-Tranejaerg syndrome</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

CoQ = coenzyme Q; NN = no name; SDH = succinate dehydrogenase gene; SURF = surfeit locus protein; LRPRRC = leucine-rich pentatricopeptid motif containing protein; COX = cytochrome-c-oxidase; BCSD1 gene = human bcl synthesis-like gene; mtDNA = mitochondrial deoxyribonucleic acid; MNGIE = neurogastrointestinal encephalomyopathy; TP = thymidin phosphorylase; MDS = mitochondrial depletion syndrome; DGUK = deoxy-guanosine-kinase; DIDMOAD = diabetes insipidus, diabetes mellitus, optic atrophy, deafness; WFS = Wolfram's syndrome; TAZ = taffazin; LVHT = left ventricular hypertrabeculation; FRAXA = frataxin; DDP1 = deafness dystonia protein 1 gene.
causes of MCPs are mutations in genes of either the mitochondrial deoxyribonucleic acid (mtDNA) or the nuclear deoxyribonucleic acid (nDNA),\textsuperscript{4} indirectly affecting mtDNA or mitochondrial function (‘nuclear’ MCPs).\textsuperscript{3} In adults half of the MCPs are due to mtDNA mutations and the other half to nDNA mutations.\textsuperscript{2} In children, the percentage of nuclear MCPs is estimated to be 80%.\textsuperscript{5} Mitochondrial and nuclear MCPs may be either sporadic or inherited. Inherited MCPs may be transmitted via an autosomal dominant, autosomal recessive, X-chromosomal, or maternal trait. The most widely appreciated mode of inheritance is that via the maternal line. Maternally inherited mtDNA mutations may simulate dominant traits because of reduced penetrance or complex interaction with genetic and environmental factors.\textsuperscript{6} Dominant traits are rare in MCPs and affect the organelle biogenesis and the integrity of the mtDNA, resulting in impaired energy supply, abnormal mitochondrial trafficking, increased toxic damage by oxygen radicals, and mitochondrially driven apoptosis.\textsuperscript{7} Both haploinsufficiency and gain-of-function mechanisms underlie nuclear MCPs.

**Mitochondrial DNA mutations**

Human mtDNA is a 16.5kb circular minichromosome consisting of two complementary strands (H and L strand). MtDNA contains 13 mt genes encoding for subunits of the respiratory chain complexes I (NADH dehydrogenase (ND)-1-4, ND4L, ND5-6), III (cytochrome b), IV (cytochrome-c-oxidase (COX)-I-III) and V (adenosine triphosphatase (ATPase) 6, ATPase8), and 24 syn genes encoding for 22 tRNAs (ribonucleic acid) and two rRNAs.\textsuperscript{8} Only the D-loop is a noncoding stretch, containing the promoters for L and H strand transcription. All coding sequences are contiguous with each other without introns.\textsuperscript{9} Since the mtDNA genetic code differs from the universal code, the expression of mtDNA genes relies on the specific mitochondrial protein synthesis, depending on the interplay between nuclear encoded transcriptional and translational factors with mitochondrial tRNAs and rRNAs.

Mitochondrial genetics differs from nuclear genetics in the following points:

1. Mitochondrial DNA is maternally inherited.
2. Mitochondria are polyploid, containing 2-10 mtDNA copies per organelle, and each cell contains hundreds of mitochondria.
3. All mtDNA copies are identical (homoplasy). The propensity of mtDNA to mutate randomly, however, results in the coexistence of wild-type mtDNA and mutant mtDNA in a single cell and organ (heteroplasmy).
4. Mitochondria and mutant mtDNA are stochastically distributed to daughter cells, resulting in changing mutation loads in different generations and increasing the phenotypic variation of MCPs (bottleneck effect).

5. Because of mitotic segregations and polyploidy, the phenotypic expression is dependent on a threshold effect. If the load of mutant mtDNA copies exceeds a certain amount, the effect of a mutation can no longer be compensated by wild-type mtDNA.

6. Phenotypic variability is additionally dependent on the pathogenicity of a mutation, the affected gene, the mutation load and its tissue distribution, and the reliance of an organ on the mitochondrial energy supply. Organs that predominantly rely on mitochondrial energy production are the eyes, ears, central and peripheral nervous systems, heart, endocrine system, kidney, guts and liver.

MtDNA mutations are divided into large-scale rearrangements (partial deletions or duplications) and inherited point mutations. Large-scale rearrangements are usually sporadic, while point mutations are usually maternally inherited. Large-scale rearrangements affect several genes and are invariably heteroplasmic, whereas point mutations affect mit and sin genes and can be heteroplasmic or homoplasmic.\textsuperscript{1,2,4,5} Phenotype expression of mtDNA mutations often requires the influence of nuclear modifier genes, environmental factors, or the presence of mtDNA haplotypes (polymorphisms). Clusters of mtDNA variants might act as predisposing haplotypes, increasing the risk of disease.\textsuperscript{7}

**Nuclear DNA mutations**

Nuclear genes involved in the development of MCPs can be subdivided into four groups: genes encoding for structural components of the respiratory chain; genes encoding for assembly factors of respiratory chain complexes; genes responsible for the mtDNA stability; and genes involved in the biogenesis of mitochondria (table 3).\textsuperscript{6} Generally, the phenotype-genotype correlation in MCPs is poor.\textsuperscript{1}

**Diagnosis**

Diagnosing MCPs is a challenge because of their wide clinical and genetic heterogeneity.\textsuperscript{1} Generally, the diagnosis is based on clinical, blood chemical, electrophysiological, imaging, histological, immunohistological, biochemical, polarographic, magnetic spectroscopic, and genetic investigations. Based on these investigations a stepwise strategy can be proposed for the diagnostic work-up (figure 1). If an adult patient presents with a classical mitochondrial syndrome MCP, such as chronic progressive external ophthalmoplegia (CPEO), Kearns-Sayre syndrome (KSS), myopathy, encephalopathy, lactacidosis and stroke-like episodes (MELAS) syndrome, myoclonic epilepsy
and ragged red fibres (MERRF) syndrome, neuropathy, ataxia, retinitis pigmentosa (NARP) syndrome, or Leber’s hereditary optic neuropathy (LHON), appropriate mtDNA studies should be carried out as a first-line investigation. If the phenotype is classic for a nuclear syndromic MCP (Leigh’s syndrome, myoneurogastrointestinal encephalopathy (MNGIE)), nDNA genetic studies should then be performed (figure 1).9

If the patient presents with nonsyndromic MCP, it is advisable to individualise the diagnostic approach,10,11 since there is no golden standard for diagnosing MCPs and since the majority of MCPs are sporadic. If the phenotype is nonsyndromic, but highly suggestive of encephalomyopathy, blood, urine or cerebrospinal fluid (CSF) studies should first be carried out and if negative, followed by a muscle biopsy for histological, immunohistological, biochemical, or polarographic investigations (figure 1).9,12 If these investigations yield negative results, but there is still suspicion of a mitochondrial MCP, sequencing the entire mtDNA should be considered. Myopathy with or without hyper-creatine-kinase-aemia or lactacidosis is the most common presenting feature.13 Phenotypes suggestive of MCP include the combinations deafness, cardiomyopathy and diabetes together with encephalomyopathy,1 short stature, deafness, and ptosis,9 or leucencephalopathy of undetermined cause, particularly if ischaemia, multiple sclerosis, and leucodystrophy have been ruled out.14 Concerning muscle biopsy, COX staining alone is not sufficient to assess the respiratory function immunohistochemically, which is why it should be always complemented by succinate dehydrogenase (SDH) staining. Generally, MCP should be considered when there is an unexplained association of abnormalities with progressive course, involving seemingly unrelated organs.11 Several research groups have developed diagnostic criteria, which may be useful for diagnosing MCPs.8,15-17

**Visceral Manifestations of Mitochondriopathies**

Visceral manifestations of MCPs concern the endocrine organs, heart, guts, liver, the kidney, and the haematopoetic system. In addition to the classical mitochondrial syndromes, which are accompanied by visceral manifestations,18 phenotypes that do not fit into one of the known mitochondrial syndromes account for the majority of MCPs with visceral manifestations.

**Endocrine Organs**

Endocrinological abnormalities represent the most frequent visceral manifestations of MCPs. Endocrine organs affected in MCPs are the pituitary gland (hypopituitarism with growth retardation, thyroid

![Figure 1. Stepwise procedure for the diagnostic work-up of mitochondriopathies](image-url)
dysfunction, hypopituitarism, or hypothyroidism, the thyroid gland (thyroiditis or Hashimoto thyroiditis), the parathyroid gland (hypoparathyroidism), the endocrine pancreas (diabetes mellitus), the suprarenal gland (hyperaldosteronism or Addison’s syndrome), or the gonads (infertility, spontaneous abortion). Symptoms of hypopituitarism or hypothyroidism may overlap with symptoms of skeletal muscle manifestations such as fatigue, general weakness, slowing, or hypotonia. Whether hyperlipidaemia, hyperuricaemia, osteoporosis, or hyperhidrosis, which are frequently associated with MCP, represent manifestations of an MCP, is unclear. Mitochondrial syndromes that go along with endocrinological manifestations are the MELAS, MERRF, KSS, maternally inherited diabetes and deafness (MIDD), and diabetes mellitus, optic atrophy, deafness (Didmoad or Wolfram) syndrome (table 2).

HEART

The heart is the visceral organ second most frequently affected in MCPs. Cardiac involvement of MCPs either manifests as impulse generation or impulse conduction disturbances or as myocardial impairment, manifesting as either hypertrophic or dilated cardiomyopathy. Frequent electrocardiography abnormalities are atrial fibrillation, atrioventricular (AV) block, Wolff-Parkinson-White (WPW) syndrome, bundle branch block, QT prolongation, or ST and T-wave abnormalities. A frequently overlooked myocardial manifestation of MCPs is left ventricular hypertrabeculation, also known as noncompaction. Noncompaction presents as a meshwork of interwoven myocardial strings, all lined with endocardium, distally to the papillary muscles. On echocardiography trabeculations have the same echogenicity as the myocardium, they move synchronously with it, and are perfused from the ventricular side. In single cases apical ballooning of the left ventricle (Takotsubo’s phenomenon) has been associated with MCPs. Since cardiac involvement in MCP may manifest subclinically, and rhythm abnormalities, hypertrophic/dilative cardiomyopathy, or noncompaction may be the initial or even exclusive manifestation of MCP, all these patients should undergo a complete neurological investigation. Vice versa, all patients in whom MCP is suspected or diagnosed should undergo a complete cardiological investigation. MCPs are frequently associated with arterial hypertension or orthostatic hypotension. Mitochondrial syndromes, with cardiac manifestations are the MELAS, MERRF, KSS, CPEO, LHON, NARP, and Leigh syndromes (table 2).

GASTROINTESTINAL TRACT

Frequent gastrointestinal manifestations of MCPs are dysphagia, in case of smooth muscle affection, hepatopathy with steatosis hepatis and liver insufficiency, or villous atrophy of the small intestines with recurrent diarrhoea. Rare gastrointestinal manifestations of MCPs are paradontosis, recurrent, sometimes triggerable vomiting, recurrent pancreatitis with exogen pancreas insufficiency, gastrointestinal dysmotility, gastroparesis, progressive intestinal pseudo-obstruction, abdominal pain, dilation and dysmotility of the oesophagus, stomach and the small intestines, and malabsorption with progressive malnutrition. Gastroscopy and colonoscopy often show nonspecific alterations. Gastrointestinal manifestations of MCPs are still underrecognised, most likely due to the difficult diagnostic approach. Biochemical or electron microscopic investigations of the affected organs and tissues may help to prove the impaired function or abnormal morphology of mitochondria. Mitochondrial syndromes with gastrointestinal manifestations are the MERRF, Pearson, MNGIE, DIDMOAD, Leigh, and mitochondrial depletion syndromes (MDS) (table 2).

KIDNEYS

Renal manifestations of MCPs are polycystic kidneys, nonspecific nephritis, focal, segmental glomerulosclerosis, or tubular dysfunction, which frequently turns into chronic renal failure, requiring haemodialysis. Proximal tubular dysfunction results in a more or less complete Toni-Debre-Fanconi syndrome, characterised by hyperphosphaturia, hyperaminoaciduria, and glucosuria. Fanconi’s syndrome may occur in an isolated form as the initial manifestation of an MCP or as part of a multisystem disease. Only a few patients have been reported with tubular acidosis, Bartter’s syndrome, chronic tubulointerstitial nephritis, or nephritic syndrome. Bicarbonaturia, hypercalcuria, proteinuria, or a decreased glomerular filtration rate may also be present. Mitochondrial syndromes with renal manifestations are the KSS, Pearson, DIDMOAD, and Leigh syndromes (table 2).

BLOOD

Rarely, MCPs manifest in the haematopoetic system as pancreatic dysfunction or as isolated thrombocytosis or thrombopenia, or as pancytopenia. In single cases either permanent or recurrent eosinophilia can be observed, not attributable to any of the established causes. Mitochondrial syndromes accompanied by alterations of
the haematopoetic system are the KSS, Pearson, MERRF, and Leigh syndromes (table 2). All these manifestations are partially resistant to adequate therapy.

Syndromic, mitochondrial MCPs with visceral manifestations

Chronic progressive external ophthalmoplegia

CPEO is the commonest manifestation of mtDNA rearrangements and often associated with ptosis. Later on, cataract, retinitis pigmentosa, deafness, fatigue, ataxia, limb weakness, neuropathy, rhythm abnormalities, cardiomyopathy, or renal insufficiency may develop. The clinical course is usually benign since additional organ failure is mild and with a low risk of serious disability. CPEO is due to mtDNA deletions or point mutations in the tRNALeu, tRNAIle, tRNAlys, or tRNAasn genes. Point mutations in the tRNALys gene cause CPEO with myoclonic epilepsy. Point mutations in the tRNALeu gene cause CPEO with multisystem involvement, CPEO with diabetes and ataxia, or CPEO with myopathy and sudden death. CPEO with multiple-sclerosis-like features is due to tRNAle mutations. CPEO with diabetes and lipoma has been reported in a patient with the A3243G mutation.

Kearns-Sayre syndrome

KSS is characterised by CPEO, pigmentary retinopathy, cardiac conduction defects, cerebellar ataxia, raised CSF protein, and onset before the age of 20. Proximal myopathy develops with progression of the disease. Additional features may be mental retardation, deafness, syncope, bulbar symptoms such as dysphagia, stroke-like episodes, endocrine dysfunction, such as delayed puberty, primary amenorrhoea, or diabetes, sideroblastic anaemia, or lactacidosis. The prognosis of KSS is poor and patients rarely survive beyond the age of 30. KSS is due to sporadic, single or multiple large-scale deletions, ranging from 1.3 to 8.8 kb or from mtDNA duplications.

Myoclonic epilepsy and ragged red fibres

MERRF syndrome usually presents between childhood and early adulthood with photosensitive general tonic-clonic seizures, myopathy, including ptosis and ophthalmoplegia, cerebellar ataxia, dementia, and deafness. Myocloni occur alone or in association with generalised seizures. Additional features include stroke-like episodes, optic atrophy, dorsal column loss, cardiomyopathy, heart block, heart failure, respiratory failure, paralytic ileus, pancytopenia, lipomatosis, pes cavus, or polyneuropathy. In a single case, carrying the A8344G mutation, histiocytoid cardiomyopathy was described. Disease severity ranges from minor, non-disabling manifestations to progressive, ultimately fatal disease. MERRF is caused by mtDNA tRNALys point mutations or multiple mtDNA deletions resulting from nDNA mutations. A mutation frequently found in MERRF patients is the mtDNA transition A8344G.

Maternally inherited diabetes and deafness

MIDD was first described in a family with only maternally inherited diabetes and sensorineural hearing loss. Later on, MIDD families were described that additionally presented with features of MELAS syndrome, including seizures, migraine, short stature, mental retardation, or stroke-like episodes. No correlation between the heteroplasmy rate and the clinical features was found. MIDD is caused by mutations in the tRNALeu or tRNAlys gene and due to large-scale tandem duplications or deletions/duplications. The most frequent mutation causing MIDD is the A3243G transition. In a single patient the A3243G mutation was associated with hypertrophic cardiomyopathy and heart failure.

Leber’s hereditary optic neuropathy

LHON is the commonest cause of maternally inherited blindness in otherwise healthy young men. LHON is due to homoplasmic mtDNA mutations affecting genes, which encode for subunits of respiratory chain complex I, III, IV, or V. There are three primary LHON mutations, A3460G, A11778G, and T14484C, which account for >95%
of the cases.53-59 Only 50% of males and 10% of females harbouring a primary LHON mutation actually develop LHON.58 The incomplete penetrance and the predominance in males suggest that factors other than mtDNA mutations (secondary LHON mutations, nDNA mutations) play a modifying role. Onset is in late adolescence or early adulthood with subacute, painless, bilateral visual loss. Rarely, the heart (rhythm abnormalities, hypertrophic cardiomyopathy, left ventricular hypertroabelcation) or cerebrum (dystonia) are additionally affected.1,13 Some female LHON patients present with a multiple sclerosis-like phenotype.68 White matter lesions were also reported in a male with the A346G mutation.19

Neuropathy, ataxia, retinitis pigmentosa
NARP syndrome is characterised by weakness due to motor neuropathy, sensory disturbances, cerebellar ataxia, and retinitis pigmentosa. Rare additional features include developmental delay, mental retardation, dementia, ataxia, cardiomyopathy, and epilepsy. NARP and NARP/maternally inherited Leigh's syndrome (MILS) overlap syndrome due to mutations in the mtDNA ATPase6 subunit gene.12,18,41

Maternally inherited Leigh's syndrome
Leigh's syndrome, also known as subacute necrotising encephalopathy, usually presents at infancy as a multisystem disorder with brainstem and basal ganglia dysfunction, weakness, hypesthesia, seizures, developmental delay, and lactacidosis. Additional features may include pyramidal signs, dystonia, optic atrophy, nystagmus, retinitis pigmentosa, ataxia, deafness, neuropathy, CPEO, or respiratory failure.42 Visceral manifestations comprise hypertrophic cardiomyopathy, fatty infiltrations of hepatocytes, recurrent vomiting, and degeneration of the renal tubular epithelial cells.44,45 Typical cerebral CT or MRI abnormalities include bilateral, symmetric, high-signal alterations in the spinal cord, upper brainstem, cerebellum, midbrain, thalamus, or basal ganglia, with or without cortical changes, and basal ganglia calcifications. Infantile-onset MILS is caused by ATPase6 mutations.44 Adult-onset MILS is caused by tRNAVal mutations.48 MILS with spinocerebellar ataxia is associated with a tRNAlys mutation.48

Nonsyndromic, mitochondrial MCPs with visceral manifestations
Mitochondrial MCPs with visceral manifestations that do not fit into one of the established mitochondrial syndromes comprise the following entities: myopathy associated with cardiomyopathy due to tRNAleu mutations;18 hypertrophic cardiomyopathy due to t2rRNA, tRNAsIle, tRNAlys, tRNAGly, or cytb mutations;18 multisystem MCP with cardiomyopathy due to the A4269G, G8363A, C4320T mutations;18 encephalomyopathy associated with diabetes due to the T14709C transition;18 congenital multisystem MCP due to the A15023G transition;18 multisystem MCP with sudden death due to the A10044G transition;18 intestinal dysfunction associated with encephalomyopathy due to the G8313A or G1644T mutations;18 idiopathic sideroblastic anaemia due to the G12301A, T6721C, or T6742C mutations;18,41 and exercise intolerance and myoglobinuria due to point mutations in the tRNAPh, COXIII, ND4, or cytb gene.18 MtDNA deletions and insertions may cause: diabetes, deafness, or maculopathy;18 diabetes, deafness, and optic atrophy;18 exercise intolerance with recurrent myoglobinuria;18 chronic diarrhoea with villous atrophy and multisystem involvement;18 diabetes, deafness, tubulopathy, and ataxia;18 or diabetes, cerebellar ataxia, hearing loss, olfactory dysfunction, CPEO, and bilateral facial nerve palsy.46

Syndromic, nuclear mitochondrialopathies with visceral manifestations
Nuclear Leigh's syndrome
Nuclear Leigh's syndrome hardly differs phenotypically from MILS. Typical clinical features are vomiting, hepatopathy, cardiomyopathy, encephalopathy, and generalised weakness. Nuclear Leigh's syndrome is caused by mutations in nDNA genes encoding for subunits of the pyruvate-dehydrogenase complex or for respiratory chain components, such as NDUFs, NDUFS7, NDUFS8, NDUFV1, or SDHA (table 3) or genes encoding for proteins involved in the maintenance of respiratory chain complex function by guaranteeing the correct holoenzyme assembly.13 The most frequently mutated gene of the latter type is surfeit locus protein (SURF1), encoding for a complex IV assembling protein.4 A French-Canadian type of Leigh's syndrome is due to mutations in the leucine-rich pentatricopeptide motif containing protein (LRPPRC) gene, encoding for a putative mtDNA transcript-processing factor.4,47

Myoneurogastrointestinal encephalopathy
MNGIE, also termed POLIP (polyneuropathy, ophthalmoplegia, leucencephalopathy, intestinal pseudo-obstruction), is a multisystem disorder manifesting before the age of 20 as episodic nausea, vomiting, gastroparesis, progressive intestinal pseudo-obstruction, abdominal pain, dilation or dysmotility of the oesophagus, stomach, or small intestine, diarrhoea, and malabsorption with progressive malnutrition, leading to death around the age of 40. Additional features comprise myopathy, including CPEO, glaucoma-like optic neuropathy, cognitive decline due to leucencephalopathy, retinitis pigmentosa, deafness, hoarseness, dysarthria, and polyneuropathy.48 Post-mortem changes include visceral neuropathy (loss of neurons and fibrosis in the celiac, mesenteric, or...
Auerbach plexuses) and scleroderma-like changes. MNGIE was recently shown to result from mutations in a gene encoding for the thymidine phosphorylase. Thymidine phosphorylase is likely to have an important role in nucleoside metabolism by regulating the availability of thymidine for DNA synthesis. Accordingly, patients harbour mtDNA deletions, multiple deletions, or point mutations. Additional functions of the enzyme involve angiogenesis and cell trophism. The disorder is transmitted via an autosomal recessive trait.

**Diabetes insipidus, diabetes mellitus, optic atrophy, deafness (Wolfram’s syndrome)**

DIDMOAD syndrome is a rare autosomal recessive neurodegenerative disorder with juvenile onset, also known as Wolfram’s syndrome (WFS). The mortality rate of WFS is about 65% before 35 years of age. Minimal diagnostic criteria include diabetes and optic atrophy, with seemingly unknown aetiology. Other less frequent features are psychiatric abnormalities, ataxia, urinary tract atony, limited joint contractures, cardiovascular and gastrointestinal autonomic neuropathy, hypergonadotropic hypogonadism, cardiac malformations, or pituitary dysfunction. WFS is genetically heterogeneous, but most frequently due to mutations in the WFS1 gene on chromosome 4p16 or mutations in the WFS2 gene on chromosome 4q22.54,55 WFS1 and WFS2 mutations secondarily result in single or multiple mtDNA deletions.

**Mitochondrial depletion syndrome**

MtDNA depletion of various degrees leads to a fatal multisystem infantile disorder, characterised by weakness, muscle hypotonia, CPEO, and severe lactacidosis. Additional features include hepatopathy, Fanconi’s syndrome, encephalopathy, seizures, cardiomyopathy, or cataract. Total mtDNA levels in these patients are below 35% of those in controls. No mtDNA mutations are found in these patients. The underlying defect is an impaired replication or maintenance of mtDNA due to nDNA mutations in the thymidine kinase or deoxyguanosine kinase gene, causing gastrointestinal abnormalities, deoxyguanosine-kinase (DGUK) gene, resulting in encephalomyopathy and hepatopathy, polymerase gamma (POLG) gene causing hepatopathy with lactacidosis, WFS1 or WFS2 genes, associated with DIDMOAD syndrome, or thymidine kinase 2 gene, associated with fatal infantile hepatopathy (table 3).

**Barth’s syndrome**

Barth’s syndrome is a rare X-linked disease, characterised by the triad dilated cardiomyopathy, skeletal myopathy, and neutropenia. Additionally, there may be growth retardation and 3-methyl-glutaric aciduria. The age range is 0 to 49 years. Untreated boys die in infancy or early childhood from septicaemia or cardiac failure. Barth’s syndrome is due to mutations in the taffazin gene on chromosome Xq28. The taffazin gene is suspected to encode for one or more acyltransferases, resulting in reduced cardiolipin synthesis and thus cardiolipin deficiency in the skeletal muscle, myocardium, and platelets. Barth’s syndrome is the first inborn error of metabolism identified, directly affecting cardiolipin, a component of the inner mitochondrial membrane, necessary for proper functioning of the electron transport chain.

**Friedreich’s ataxia**

Friedreich’s ataxia is the most common of the inherited ataxias. Clinically, Friedreich’s ataxia is characterised by cerebellar ataxia, hypertrophic cardiomyopathy, and foot deformity. Friedreich’s ataxia is caused by an expansion of a GAA triplet, located within the first intron of the frataxin gene on chromosome 9q13. The mutation affects mitochondria because of its involvement in RNA processing and the intramitochondrial iron handling, leading to iron accumulation, increased sensitivity to oxidative stress, and deficient respiratory chain activity. There are indications that the mutation results in a defect of iron/sulphur protein construction.

**Mohr-Tranebjaerg syndrome**

Mohr-Tranebjaerg syndrome (MTS) is a rare disorder characterised by early-onset deafness, dystonia, cortical blindness, cataract, spasticity, dysphagia, and mental retardation. MTS is due to mutations in the gene encoding for the deafness-dystonia protein (DDP1). The first mutation found in this gene was the C66W missense mutation, affecting the binding of Zn(2+) via the Cys(4) motif. As a consequence, the DDP1 molecule is incorrectly folded and loses its ability to assemble to a heterohexameric complex with its cognate partner Tim13. In a recently described patient MTS was due to the G38C transversion in exon 1 of the DDP1 gene, affecting the ATG start codon by changing methionine to isoleucine. This mutation leads to the absence of DDP1 and marked reduction of Tim13. Other mutations reported were the one basepair deletion 151delT and the stop mutation E24X in the allelic Jansen’s syndrome.

**Nuclear chronic progressive external ophthalmoplegia**

CPEO due to mutations in nuclear genes may also present with visceral manifestations, similar to those in mitochondrial CPEO. Mutated genes responsible for nuclear CPEO are due to mutations in the twinkle, ANT1, or POLG genes.
Nuclear myoclonic epilepsy and ragged red fibres
MERRF syndrome is not only due to mtDNA mutations but also due to mutations in the POLG gene (nuclear MERRF). The clinical features of nuclear MERRF are the same as those of mitochondrial MERRF.

Nonsyndromic, nuclear mitochondriopathies with visceral manifestations
Nonsyndromic, nuclear MCPs with visceral manifestations include fatal, multisystem complex I deficiency due to mutations in the NDUFS4 gene; familial idiopathic cardiomyopathy due to multiple, secondary mtDNA deletions; sideroplasic anaemia with myopathy; CPEO with cardiomyopathy due to multiple, secondary mtDNA deletions; thiamine-responsive megaloblastic anaemia; mitochondrial diabetes; pheochromocytoma and cervical paraganglioma due to SDHB mutations; hereditary paragangliomas due to SDHC or SDHD mutations; pyruvate dehydrogenase complex deficiency characterised by neutropenia, absent corpus callosum, absent pyramids, and ectopic inferior olives; Luft’s syndrome; X-linked ataxia with sideroblastic anaemia; hepatopathy with ketoadicotic coma due to SCO1 mutations; leucodystrophy with tubulopathy due to COX10 mutations; and hypertrophic cardiomyopathy due to COX15 mutations. Whether arteriosclerosis is a feature of MCPs remains speculative.

THERAPY
Systematic studies on therapies for MCPs are lacking. There is no causal, only symptomatic therapy of MCPs. Symptomatic therapy comprises antidiabetic therapy in case of diabetes, hormone substitution in case of other endocrine disturbances, cardiac therapy in case of rhythm abnormalities or heart failure, antiemetic drugs if there is vomiting, substitution of pancreatic enzymes, domperidone or cisapride for gastrointestinal dysmotility, substitution of potassium and sodium in case of hypokalaemia or hyponatraemia, hormone substitution in case of hypotuitarism, and transfusions for anaemia and pancytopenia. Symptomatic measures may markedly improve quality of life and prognosis of affected individuals. Substitution of coenzyme-Q is effective only in case of confirmed coenzyme-Q-deficiency. Idebenone has a positive influence on hypertrophic cardiomyopathy in patients with Friedreich’s ataxia. If dysphagia, frequent vomiting, malabsorption, or recurrent diarrhoea leads to prominent cachexia, a percutaneous gastroenterostomy should be considered. Impaired impulse propagation in KSS or other MCPs often requires the implantation of a pacemaker already at the early stages of the disease. If there is coexisting carnitine deficiency, administration of carnitine can be helpful. Ptosis often requires surgical reconstruction.

PROPHYLAXIS
More important than the administration of certain drugs is the avoidance of certain, frequently prescribed remedies, such as biguanides (cause lactacidosis), fibrates, or local anaesthetics such as bupivacain or articain (inhibit respiratory chain complex I), statins (reduce endogenous coenzyme Q10), acetyl-salicylic-acid or sevofoflurane (inhibit the respiratory chain electron transport), β-blockers (inhibit non competitively the ATPase and thus stage 3 respiration), carvedilol (inhibits complex I), corticosteroids (reduce the transmembrane mitochondrial potential), tetracyclines and amiodarone (inhibit the β-oxidation), barbiturates, chloramphenicol (reduce mitochondrial protein synthesis and number and size of mitochondria), and valproic acid (sequesters carnitine, reduces respiratory chain activity and oxidative phosphorylation), doxorubicine, ifosamide, and carboplatin (cause mtDNA mutations), zidovudine (causes mtDNA depletion, reduces respiratory chain complex I and IV activity), and interferon (impairs the mtDNA transcription). Generally, care should be taken when applying local anaesthetics and with general anaesthesia. MCP patients also should avoid exposure to ozone.

SUMMARY
MCPs are usually multisystem disorders, which, in addition to the central and peripheral nervous systems, eyes, or ears, also manifest in visceral organs, such as endocrine organs, heart, gastrointestinal tract, liver, kidneys, or haematopoetic system. This is why the internal medicine specialist plays an important role in the diagnostic work-up and symptomatic therapy of these disorders. Internal medicine specialists should consider an MCP if a patient or family presents with a combination of endocrine dysfunctions, rhythm abnormalities, cardiomyopathy, arterial hypo- or hypertension, hepatopathy, gastrointestinal dysfunction, renal insufficiency, thrombocytopenia, or anaemia alone or in combination, without an explanation for any of these abnormalities. Since most MCPs are accompanied by neurological abnormalities, it is advisable to refer any patient with suspected MCP to a neurologist who is familiar with MCPs. All patients in whom MCP is suspected or diagnosed should also undergo ophthalmological, otolaryngological, endocrinological, cardiological, gastrointestinal, and haematological investigations. Although there is no causal therapy for MCPs, adequate symptomatic therapy,
particularly of the visceral manifestations, may result in a markedly improved quality of life and prognosis of these still often neglected or overlooked entities.

REFERENCES


Finsterer. Overview on visceral manifestations of mitochondrial disorders.